Skip to main content
OpenTrials
Completed

NCT Number: NCT05571163

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

The primary objective of the study is to evaluate the pharmacokinetics (PK) of AMG 510 administered as 8 x 120-mg tablets and as water dispersion in healthy participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Participants

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Covance Clinical Research Unit, Inc 1341 W Mockingbird Ln, Ste 200E

Dallas, Texas, 75247, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects or healthy female between 18 and 55 years of age (inclusive) at the time of Screening.
  • Body mass index between 18 and 30 kg/m2 (inclusive) at the time of Screening.
  • Females of nonchildbearing potential

Exclusion criteria

  • History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Inability to swallow oral medication or history of malabsorption syndrome.
  • Poor peripheral venous access.
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.

Treatment and study plan

AMG 510

Drug

Tablets

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of AMG 510

    Time frame: Day 1 and Day 4

  2. Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 510

    Time frame: Day 1 and Day 4

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 510

    Time frame: Day 1 and Day 4

Secondary outcomes

  1. Number of Participants with an Adverse Event (AE)

    Time frame: Day 1 to Day 6

    An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs .

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

An Open-label, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Subjects

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 7, 2022
Registry last updated
Oct 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.